Cited by 317Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsCancer-related Molecular Pathways

Constitutive telomerase expression promotes mammary carcinomas in aging mice

Open access
Artandi, Steven E., Alson, Scott, Tietze, Maja K., Sharpless, Norman E., Ye, Siqin, Greenberg, Roger A., Castrillon, Diego H., Horner, James W. +3 more·2002·Proceedings of the National Academy of Sciences

Abstract

Telomerase is up-regulated in the vast majority of human cancers and serves to halt the progressive telomere shortening that ultimately blocks would-be cancer cells from achieving a full malignant phenotype. In contrast to humans, the laboratory mouse possesses long telomeres and, even in early generation telomerase-deficient mice, the level of telomere reserve is sufficient to avert telomere-based checkpoint responses and to permit full malignant progression. These features in the mouse provide an opportunity to determine whether enforced high-level telomerase activity can serve functions that extend beyond its ability to sustain telomere length and function. Here, we report the generation and characterization of transgenic mice that express the catalytic subunit of telomerase (mTERT) at high levels in a broad variety of tissues. Expression of mTERT conferred increased telomerase enzymatic activity in several tissues, including mammary gland, splenocytes, and cultured mouse embryonic fibroblasts. In mouse embryonic fibroblasts, mTERT overexpression extended telomere lengths but did not prevent culture-induced replicative arrest, thus reinforcing the view that this phenomenon is not related to occult telomere shortening. Robust telomerase activity, however, was associated with the spontaneous development of mammary intraepithelial neoplasia and invasive mammary carcinomas in a significant proportion of aged females. These data indicate that enforced mTERT expression can promote the development of spontaneous cancers even in the setting of ample telomere reserve.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.112515399

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Overexpression of mouse telomerase reverse transcriptase catalytic subunit induces a variety of malignancies.

    “Overexpression of the mouse telomerase reverse transcriptase catalytic subunit (mTERTcs) has been shown to induce a variety of malignancies64–66.”
  • Increased telomerase activity in two independent Tert transgenic mouse models seemed to increase susceptibility to tumour formation.

    “One caveat to such an approach is the observation that increased telomerase activity in two independent Tert transgenic mouse models seemed to increase the susceptibility for tumour formation 66, 67 .”

    From The common biology of cancer and ageing (2007) · cites this paper as [67]

  • TERT promotes tumor development even in settings of ample telomere reserve.

    “Moreover, recent findings indicate that TERT promotes tumor development even in settings of ample telomere reserve, although the mechanisms underlying these telomere length-independent activities of TERT remain unclear9–13.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [22]Ogoshi M, Takashima A, Taylor R S. J Immunol. 1997;158:622–628. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/8992976/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Immunol&author=M%20Ogoshi&author=A%20Takashima&author=R%20S%20Taylor&volume=158&publication_year=1997&pages=622-628&pmid=8992976&)]
  2. [23]Hathcock K S, Weng N P, Merica R, Jenkins M K, Hodes R. J Immunol. 1998;160:5702–5706. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/9637478/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Immunol&author=K%20S%20Hathcock&author=N%20P%20Weng&author=R%20Merica&author=M%20K%20Jenkins&author=R%20Hodes&volume=160&publication_year=1998&pages=5702-5706&pmid=9637478&)]

Cited by

Sorted by citations

Authors
Artandi, S. E., Alson, S., Tietze, M. K., Sharpless, N. E., Ye, S., Greenberg, R. A., Castrillon, D. H., Horner, J. W., Weiler, S. R., Carrasco, R. D., & DePinho, R. A.
Affiliations
  • Brigham and Women's Hospital (US)
  • Department of Adult Oncology, Dana–Farber Cancer Institute, Harvard Medical School, 44 Binney Street (M413), Boston, MA 02115; Departments of Medicine and Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; Department of Genetics, Harvard Medical School, Boston, MA 02115; and Department of Hematology, Cancer Biology Program, Stanford University School of Medicine, Stanford, CA 94305
Corresponding author
DePinho, Ronald A.
Venue
Proceedings of the National Academy of Sciences
Published
2002-05-28
Volume
99
Issue
12
Pages
8191-8196
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2148531499
Cited by
317
References
37
Citations by year
2026: 2 · 2025: 1 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 7 · 2020: 7 · 2019: 3 · 2018: 13 · 2017: 10 · 2016: 13 · 2015: 9 · 2014: 7 · 2013: 16 · 2012: 21
FWCI
17.58
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Cancer Society
  • National Institutes of Health
  • National Institute on Aging (K08 AG0103)
  • National Cancer Institute (KO8 CA 82176, K08 CA 84044, U01CA84313, U01CA084313, K08CA084044, R01CA84628, K08CA082176, R01CA084628)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
telomerase, breast cancer, mammary intraepithelial neoplasia, transgenic mice, telomere length, replicative senescence, aging
MeSH terms
Aging, Animals, Cloning, Molecular, DNA-Binding Proteins, Female, Kinetics, Mammary Neoplasms, Experimental, Mice, Transgenic, 9,10-Dimethyl-1,2-benzanthracene, Gene Expression, Open Reading Frames, Telomere, Mice, Knockout, Telomerase, Catalytic Domain, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review